Although CD31+ naïve CD4+ T cells were already described in 2002, no follow-up studies have validated CD31 as a functional biomarker of immunocompetence, e.g., protection after immunizations with neoantigens in elderly persons or decreased risk of influenza-associated hospitalization. The gene discussed is PECAM1; the disease is influenza.